Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Reports Q2 2020 Results and Business Updates

PR Newswire August 7, 2020

Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles

PR Newswire July 8, 2020

Pulmatrix Announces Changes to Board of Directors

PR Newswire June 26, 2020

Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually

PR Newswire May 27, 2020

Pulmatrix Reports Q1 2020 Results

PR Newswire May 14, 2020

Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire April 16, 2020

Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19

PR Newswire April 16, 2020

Pulmatrix Reports 2019 Financial Results and Provides Business Update

PR Newswire March 26, 2020

Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA

PR Newswire January 30, 2020

Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire January 16, 2020

Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies

PR Newswire January 6, 2020

Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

PR Newswire January 2, 2020

Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors

PR Newswire November 4, 2019

Pulmatrix Reports Q3 2019 Results

PR Newswire November 1, 2019

Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

PR Newswire September 18, 2019

Pulmatrix Receives US Patent Covering iSPERSE(TM) Formulations for Pulmazole Program

PR Newswire August 19, 2019

Pulmatrix Reports Q2 2019 Results

PR Newswire August 5, 2019

Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study

PR Newswire July 9, 2019

Pulmatrix Reports Q1 2019 Results

PR Newswire May 15, 2019

Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)

PR Newswire April 15, 2019